Imaging Markers of Brain Frailty and Outcome in Patients With Acute Ischemic Stroke.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
03 2021
Historique:
pubmed: 29 1 2021
medline: 15 12 2021
entrez: 28 1 2021
Statut: ppublish

Résumé

Functional outcome after stroke may be related to preexisting brain health. Several imaging markers of brain frailty have been described including brain atrophy and markers of small vessel disease. We investigated the association of these imaging markers with functional outcome after acute ischemic stroke. We retrospectively studied patients with acute ischemic stroke enrolled in the AXIS-2 trial (AX200 in Ischemic Stroke Trial), a randomized controlled clinical trial of granulocyte colony-stimulating factor versus placebo. We assessed the ratio of brain parenchymal volume to total intracerebral volumes (ie, the brain parenchymal fraction) and total brain volumes from routine baseline magnetic resonance imaging data obtained within 9 hours of symptom onset using the unified segmentation algorithm in SPM12. Enlarged perivascular spaces, white matter hyperintensities, lacunes, as well as a small vessel disease burden, were rated visually. Functional outcomes (modified Rankin Scale score) at day 90 were determined. Logistic regression was used to test associations between brain imaging features and functional outcomes. We enrolled 259 patients with a mean age of 69±12 years and 46 % were female. Increased brain parenchymal fraction was associated with higher odds of excellent outcome (odds ratio per percent increase, 1.078 [95% CI, 1.008-1.153]). Total brain volumes and small vessel disease burden were not associated with functional outcome. An interaction between brain parenchymal fraction and large vessel occlusion on excellent outcome was not observed. Global brain health, as assessed by brain parenchymal fraction on magnetic resonance imaging, is associated with excellent functional outcome after ischemic stroke. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT00927836.

Sections du résumé

BACKGROUND AND PURPOSE
Functional outcome after stroke may be related to preexisting brain health. Several imaging markers of brain frailty have been described including brain atrophy and markers of small vessel disease. We investigated the association of these imaging markers with functional outcome after acute ischemic stroke.
METHODS
We retrospectively studied patients with acute ischemic stroke enrolled in the AXIS-2 trial (AX200 in Ischemic Stroke Trial), a randomized controlled clinical trial of granulocyte colony-stimulating factor versus placebo. We assessed the ratio of brain parenchymal volume to total intracerebral volumes (ie, the brain parenchymal fraction) and total brain volumes from routine baseline magnetic resonance imaging data obtained within 9 hours of symptom onset using the unified segmentation algorithm in SPM12. Enlarged perivascular spaces, white matter hyperintensities, lacunes, as well as a small vessel disease burden, were rated visually. Functional outcomes (modified Rankin Scale score) at day 90 were determined. Logistic regression was used to test associations between brain imaging features and functional outcomes.
RESULTS
We enrolled 259 patients with a mean age of 69±12 years and 46 % were female. Increased brain parenchymal fraction was associated with higher odds of excellent outcome (odds ratio per percent increase, 1.078 [95% CI, 1.008-1.153]). Total brain volumes and small vessel disease burden were not associated with functional outcome. An interaction between brain parenchymal fraction and large vessel occlusion on excellent outcome was not observed.
CONCLUSIONS
Global brain health, as assessed by brain parenchymal fraction on magnetic resonance imaging, is associated with excellent functional outcome after ischemic stroke. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT00927836.

Identifiants

pubmed: 33504185
doi: 10.1161/STROKEAHA.120.029841
doi:

Substances chimiques

Granulocyte Colony-Stimulating Factor 143011-72-7

Banques de données

ClinicalTrials.gov
['NCT00927836']

Types de publication

Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1004-1011

Auteurs

Ning Bu (N)

Department of Neurology, the Second Affiliated Hospital of Xi'an Jiaotong University (N.B.).

Mohamed Salah Khlif (MS)

Dementia Theme (M.S.K., A.B.), The Florey Institute of Neuroscience and Mental Health.

Robin Lemmens (R)

Department of Neurosciences, Experimental Neurology, KU Leuven-University of Leuven, Belgium (R. Lemmens, A.W.).
Laboratory of Neurobiology, VIB, Center for Brain & Disease Research, Leuven, Belgium (R. Lemmens, A.W.).
Department of Neurology (R. Lemmens, A.W.), University Hospitals Leuven, Belgium.

Anke Wouters (A)

Department of Neurosciences, Experimental Neurology, KU Leuven-University of Leuven, Belgium (R. Lemmens, A.W.).
Laboratory of Neurobiology, VIB, Center for Brain & Disease Research, Leuven, Belgium (R. Lemmens, A.W.).
Department of Neurology (R. Lemmens, A.W.), University Hospitals Leuven, Belgium.

Jochen B Fiebach (JB)

Center for Stroke Research, Charité, Berlin, Germany (J.B.F.).

Angel Chamorro (A)

Department of Neurology, University of Barcelona, Spain (A.C.).

E Bernd Ringelstein (EB)

Wilhelms University of Muenster, Germany (E.B.R.).

Bo Norrving (B)

Department of Clinical Sciences, Section of Neurology, Lund University, Sweden (B.N.).

Rico Laage (R)

Clinical Research Department, GUIDED Development GmbH, Heidelberg, Germany (R. Laage).

Martin Grond (M)

Department of Neurology, Kreisklinikum Siegen, and University of Marburg Germany (M.G.).

Guido Wilms (G)

Department of Radiology (G.W.), University Hospitals Leuven, Belgium.

Amy Brodtmann (A)

Dementia Theme (M.S.K., A.B.), The Florey Institute of Neuroscience and Mental Health.

Vincent Thijs (V)

Stroke Division (V.T.), The Florey Institute of Neuroscience and Mental Health.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH